In vivo expression of natural killer cell inhibitory receptors by human melanoma-specific cytolytic T lymphocytes

被引:178
作者
Speiser, DE
Pittet, MJ
Valmori, D
Dunbar, R
Rimoldi, D
Liénard, D
MacDonald, HR
Cerottini, JC
Cerundolo, V
Romero, P
机构
[1] CHU Vaudois, Ludwig Inst Canc Res, Div Clin Oncoimmunol, Lausanne Branch, CH-1011 Lausanne, Switzerland
[2] John Radcliffe Hosp, Nuffield Dept Med, Inst Mol Med, Oxford OX3 9DU, England
[3] Ludwig Inst Canc Res, Lausanne Branch, CH-1066 Epalinges, Switzerland
[4] CHU Vaudois, Multidisciplinary Oncol Ctr, CH-1011 Lausanne, Switzerland
关键词
cytolytic T lymphocytes; natural killer receptors; melanoma; tumor immunity; peptide antigen;
D O I
10.1084/jem.190.6.775
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Natural killer (NK) receptor signaling can lead to reduced cytotoxicity by NK cells and cytolytic T lymphocytes (CTLs) in vitro. Whether T cells are inhibited in vivo remains unknown, since peptide antigen-specific CD8(+) T cells have so far not been found to express NK receptors in vivo. Here we demonstrate that melanoma patients may bear tumor-specific CTLs expressing NK receptors. The lysis of melanoma cells by patient-derived CTLs was inhibited by the NK receptor CD94/NKG2A. Thus, tumor-specific CTL activity may be decreased through NK receptor triggering in vivo.
引用
收藏
页码:775 / 782
页数:8
相关论文
共 52 条
[1]   Phenotypic analysis of antigen-specific T lymphocytes [J].
Altman, JD ;
Moss, PAH ;
Goulder, PJR ;
Barouch, DH ;
McHeyzerWilliams, MG ;
Bell, JI ;
McMichael, AJ ;
Davis, MM .
SCIENCE, 1996, 274 (5284) :94-96
[2]  
AZUMA M, 1993, J IMMUNOL, V150, P1147
[3]  
Bakker ABH, 1998, J IMMUNOL, V160, P5239
[4]   TUMOR-ANTIGENS RECOGNIZED BY T-LYMPHOCYTES [J].
BOON, T ;
CEROTTINI, JC ;
VANDENEYNDE, B ;
VANDERBRUGGEN, P ;
VANPEL, A .
ANNUAL REVIEW OF IMMUNOLOGY, 1994, 12 :337-365
[5]   Recognition of human histocompatibility leukocyte antigen (HLA)-E complexed with HLA class I signal sequence-derived peptides by CD94/NKG2 confers protection from natural killer cell-mediated lysis [J].
Borrego, F ;
Ulbrecht, M ;
Weiss, EH ;
Coligan, JE ;
Brooks, AG .
JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 187 (05) :813-818
[6]   LYMPHOCYTE-ACTIVATION IN HIV-1 INFECTION .2. FUNCTIONAL DEFECTS OF CD28- T-CELLS [J].
BORTHWICK, NJ ;
BOFILL, M ;
GOMBERT, WM ;
AKBAR, AN ;
MEDINA, E ;
SAGAWA, K ;
LIPMAN, MC ;
JOHNSON, MA ;
JANOSSY, G .
AIDS, 1994, 8 (04) :431-441
[7]   HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C [J].
Braud, VM ;
Allan, DSJ ;
O'Callaghan, CA ;
Söderström, K ;
D'Andrea, A ;
Ogg, GS ;
Lazetic, S ;
Young, NT ;
Bell, JI ;
Phillips, JH ;
Lanier, LL ;
McMichael, AJ .
NATURE, 1998, 391 (6669) :795-799
[8]  
COHEN EP, 1994, SEMIN CANCER BIOL, V5, P419
[9]   A common inhibitory receptor for major histocompatibility complex class I molecules on human lymphoid and myelomonocytic cells [J].
Colonna, M ;
Navarro, F ;
Bellon, T ;
Llano, M ;
Garcia, P ;
Samaridis, J ;
Angman, L ;
Cella, M ;
LopezBotet, M .
JOURNAL OF EXPERIMENTAL MEDICINE, 1997, 186 (11) :1809-1818
[10]   A NEW GENE CODING FOR A DIFFERENTIATION ANTIGEN RECOGNIZED BY AUTOLOGOUS CYTOLYTIC T-LYMPHOCYTES ON HLA-A2 MELANOMAS [J].
COULIE, PG ;
BRICHARD, V ;
VANPEL, A ;
WOLFEL, T ;
SCHNEIDER, J ;
TRAVERSARI, C ;
MATTEI, S ;
DEPLAEN, E ;
LURQUIN, C ;
SZIKORA, JP ;
RENAULD, JC ;
BOON, T .
JOURNAL OF EXPERIMENTAL MEDICINE, 1994, 180 (01) :35-42